Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Obama Calls for Generic Biotech Drugs

By Pharmaceutical Processing | February 27, 2009

By RICARDO ALONSO-ZALDIVAR Associated Press Writer WASHINGTON (AP) — President Barack Obama’s budget aims to foster generic competition for costly biotech drugs used to treat cancer and other intractable ailments. With Americans now spending more than $40 billion a year on such medications, the budget calls on Congress to set up a framework for regulators to approve generic versions, cutting costs for government programs, employers and patients. Biologic drugs are produced from living organisms — not from chemicals. They are often the first-line treatments for diseases that involve the immune system, such as cancer, rheumatoid arthritis and multiple sclerosis. But the medications are among the costliest, with many easily exceeding $1,000 a month. When the patent expires on a drug made from chemicals, generic manufacturers can enter the market by showing the Food and Drug Administration that their version contains the same active ingredients, and is identical in strength, dosage and other characteristics to the brand medication. The generic company does not have to replicate all the tests that went into developing the original medication. That regulatory shortcut dramatically lowers the cost of developing a generic drug, allowing patients to save an estimated $8 billion to $10 billion a year at pharmacies. But there’s no such process for approving generic versions of biologic drugs. Debate over the issue has dragged on for years over issues of quality and equitable treatment for the innovator companies that invest in developing the original version of a medication. One thorny question involves whether biologic drugs should get protection from competition for longer than the 20 years from submission of a patent now generally given. Obama’s budget called for resolving that debate. “The administration will accelerate access to make affordable generic biologic drugs available through the establishment of a workable regulatory, scientific and legal pathway,” said the budget documents. The administration said it will work also to prevent biologic manufacturers from reformulating brand name drugs so that a slight change wins them additional years of patent protection. Rep. Henry Waxman, D-Calif., long an advocate for generics, said he is “delighted” with the administration’s endorsement. “Legislation to permit FDA to approve generic biologics is one of my highest priorities this year,” said Waxman, who chairs the House Energy and Commerce Committee. “I am in full agreement with the president that such a program will be self-defeating if it provides monopoly periods to brand name biotech drugs that are significantly greater than those currently provided to traditional drugs.”

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE